36. Epidermolysis bullosa Clinical trials / Disease details

Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05157958 (ClinicalTrials.gov)	November 1, 2022	2/12/2021	Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa	Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) Patients	Dystrophic Epidermolysis Bullosa	Biological: ALLO-ASC-SHEET;Other: Vehicle Control	Anterogen Co., Ltd.	NULL	Not yet recruiting	4 Years	60 Years	All	6	Phase 2	NULL
2	NCT03752905 (ClinicalTrials.gov)	January 9, 2019	19/11/2018	A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Recessive Dystrophic Epidermolysis Bullosa	Drug: PTR-01;Drug: Normal saline	Phoenix Tissue Repair, Inc.	NULL	Completed	16 Years	N/A	All	12	Phase 1/Phase 2	United States
3	NCT03183934 (ClinicalTrials.gov)	July 2017	8/6/2017	A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial	A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101	Dystrophic Epidermolysis Bullosa	Biological: ALLO-ASC-DFU	Anterogen Co., Ltd.	NULL	Not yet recruiting	2 Years	60 Years	All	5	Phase 1/2	Korea, Republic of